One-sided price-cut plan should be reconsidered, a lawmaker says

The government will have to reconsider its scheme to press pharmaceutical firms to lower drug prices, which is likely to damage the profits of the domestic medical sector, a lawmaker claimed.

"We can't agree that pharmaceutical companies and medical institutions are solely responsible for the rebate issue. The government should revise the flawed system first,” Rep. Won Hee-mok said during th...